Patents Assigned to Inserm
  • Anti-CD28 Humanized Antibodies
    Publication number: 20170114136
    Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 27, 2017
    Applicants: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche M edicale (INSERM)
    Inventors: Caroline Mary, Nicolas Poirier, Bernard Vanhove
  • Composition including the HIP/PAP protein or one of the derivatives thereof for treating insulin resistance
    Patent number: 9629896
    Abstract: The invention relates to a HIP/PAP protein or to one of the derivatives thereof for use thereof for treating or preventing insulin resistance in non-insulin dependent subjects.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: April 25, 2017
    Assignees: ALFACT INNOVATION, INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS SUD, UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Fabrizio Andreelli, Paul Amouyal, Christophe Magnan, Celine Cruciani-Guglielmacci, Jamila Vaivre, Marion Darnaud, Laure Jamot, Christian Brechot, Gilles Amouyal
  • Microsphere compositions, preparation method and applications thereof
    Patent number: 9629811
    Abstract: A cell carrying microsphere composition, wherein the microsphere composition comprises a microspheric core comprising a triblock copolymer matrix A-B-A wherein A is selected from poly(lactide-co-glycolide) (PLGA) or polylactide (PLA) and B is poloxamer or poloxamine, wherein the microspheric core is coated with a cell adhesion coating and further comprises whole cells or cell fragments bonded to the cell adhesion coating, a process for the preparation of a cell carrying microsphere composition, and applications thereof.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: April 25, 2017
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Marie Morille, Van-Thanh Tran, Xavier Garric, Jean Coudane, Marie-Claire Venier-Julienne, Claudia Montero-Menei
  • Peptide antagonists of the vasopressin-2 receptor
    Patent number: 9631001
    Abstract: The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 25, 2017
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITY OF REGENSBURG, UNIVERSITY DE LIEGE
    Inventors: Nicolas Gilles, Denis Servent, Loïc Quinton, Helen Reinfrank, Ralph Witzgall, Bernard Mouillac, Christiane Mendre
  • Bioprinting station, assembly comprising such bioprinting station and bioprinting method
    Patent number: 9629989
    Abstract: Bioprinting station (1) comprising:—a Bioprinting device (4) adapted to deposit a pattern of biological material (2) onto an area of interest (3a) of a substrate (3),—an imaging system (15) adapted to acquire an image of the substrate (3) and to reveal on the acquired image the area of interest (3a) with respect to a remaining part (3b) of the substrate (3), the acquired image of the substrate (3) being processed so as to detect the revealed area of interest (3a) on the acquired image and to determine the pattern corresponding to the area of interest (3a) detected on the acquired image.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 25, 2017
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Fabien Guillemot, Sylvain Catros, Virginie Keriquel, Jean-Christophe Fricain
  • Sodium thiosulphate for the treatment of ectopic calcifications
    Patent number: 9629872
    Abstract: The present invention relates to pharmaceutical compositions comprising sodium thiosulphate dispersed in a hydrophile-in-lipophile emulsion, and the use thereof for topical administration for the treatment of an ectopic calcification and/or of the consequences thereof in an individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in addition, a hydrophile-in-lipophile emulsion. The invention also relates to a method for preparing these pharmaceutical compositions.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: April 25, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LIMOGES, CHU DE LIMOGES, UNIVERSITE PARIS-SUD
    Inventors: Voa Ratsimbazafy, Jeremy Jost, Vincent Guigonis, Eric Caudron
  • Chitosan hydrogel for repairing nerve tissue
    Patent number: 9623044
    Abstract: The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 ?m (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: April 18, 2017
    Assignees: UNIVERSITE CLAUDE BERNARD LYON I, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE JEAN MONNET, SAINT ETIENNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Fatiha Nothias, Sylvia Soares, Laurent David, Alexandra Montembault
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 9624479
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: April 18, 2017
    Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
    Publication number: 20170100378
    Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
    Type: Application
    Filed: June 9, 2015
    Publication date: April 13, 2017
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DA LA RECHERCHE MÉDICALE)
    Inventor: Olivier HERMINE
  • Monoclonal antibodies to progastrin and their uses
    Patent number: 9611320
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: April 4, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS), LES LABORATOIRES SERVIER
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Methods and compositions for the treatment of fluid accumulation in and/or under the retina
    Patent number: 9610294
    Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: April 4, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Francine Behar-Cohen, Nicolette Farman, Frederic Jaisser
  • Human soluble CD146, preparation and uses thereof
    Patent number: 9605048
    Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: March 28, 2017
    Assignees: UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Françoise Dignat-George
  • Methods for selecting binders by phage display and masked selection
    Patent number: 9605257
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 28, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Methods for expressing a polynucleotide of interest in the retina of a subject
    Patent number: 9597415
    Abstract: Provided herein are methods for expressing a polynucleotide of interest in the retina of a subject. In particular, a method for expressing a polynucleotide of interest in the retina of a subject comprising the step consisting of injecting into the vitreous an amount of a vector containing the polynucleotide of interest in combination with an amount of an inhibitor of Dp71 expression is provided.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: March 21, 2017
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Deniz Dalkara, Alvaro Rendon Fuentes, Jose Alain Sahel, Ophelie Vacca
  • POOLED NK CELLS FROM OMBILICAL CORD BLOOD AND THEIR USES FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIOUS DISEASE
    Publication number: 20170073637
    Abstract: The invention relates to the field of cell therapy, particularly NK cell mediated therapy. The present invention relates to a method of producing an ex vivo population of cells, preferably NK cells, from at least two umbilical cord blood units (UCB units), or fraction thereof containing said cells, by pooling said at least two UCB units to produce said population of cells. The present invention relates to the use of said cells, preferably NK cells, obtainable or obtained by the process according to the invention, as a composition for therapeutic use, preferably for the treatment of cancer and chronic infectious disease.
    Type: Application
    Filed: March 9, 2015
    Publication date: March 16, 2017
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE RECHERCHE MEDICALE (INSERM)
    Inventors: Patrick HENNO, Martin VILLALBA GONZALEZ
  • Detection of SHED CD31, Diagnosis of Atherothrombosis and Autoimmune Disorders, and Methods for Analyzing Signaling Pathways
    Publication number: 20170074891
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.
    Type: Application
    Filed: December 16, 2014
    Publication date: March 16, 2017
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Natural killer p30 (NKp30) dysfunction and the biological applications thereof
    Patent number: 9593376
    Abstract: The present invention relates to a method of assessing a favorable or, on the contrary, an unfavorable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of cancer in the subject.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: March 14, 2017
    Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Laurence Zitvogel, Nicolas Delahaye
  • 28 kDa GST proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a Th1 and/or Th17 response
    Patent number: 9593313
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 14, 2017
    Assignees: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • Method for the treatment of cardiovascular fibrosis
    Patent number: 9594083
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad